← Back to all trials
Recruiting
NCT07566286
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
Conditions: Chin Augmentation
Sex: All
Ages: 22 Years – N/A
Healthy volunteers: Yes
Phase: NA
Enrollment: 100
Sponsor: Galderma R&D
Location: Galderma Investigational Site # 8680 Westport Connecticut
Summary
The primary objective of this study is to evaluate the safety of Restylane Lyft with Lidocaine for augmentation of the chin region 3 months after retreatment.
Eligibility Criteria
Inclusion Criteria:
1. Males or non-pregnant, non-breastfeeding females, 22 years of age or older.
2. Intent to receive treatment for augmentation and correction of retrusion in the chin region.
Exclusion Criteria:
1. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram positive bacterial proteins.
2. Known/previous allergy or hypersensitivity to local anesthetics, e.g. lidocaine or other amide-type anesthetics.
3. Previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions.
4. Previous facial surgery (including facial aesthetic surgery and liposuction), below the level of the horizontal line from subnasale.
5. Any previous aesthetic procedures or implants.
6. Presence of any disease or lesions near or on the area to be treated.
Source: ClinicalTrials.gov (NCT07566286). StuddyBuddy aggregates publicly available trial information.